EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid

Belen de Nicolas-Ruanes, Asuncion Ballester-Martinez iD, Emilio Garcia-Mouronte iD, Emilio Berna-Rico iD, Carlos Azcarraga-Llobet, Montserrat Fernandez-Guarino

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242316786 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Belen de Nicolas-Ruanes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Dipeptidyl-Peptidase IV Inhibitors, Autoimmune Diseases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bullous pemphigoid (BP), the most common autoimmune blistering disease, is characterized by the presence of autoantibodies targeting BP180 and BP230 in the basement membrane zone. This leads to the activation of complement-dependent and independent pathways, resulting in proteolytic cleavage at the dermoepidermal junction and an eosinophilic inflammatory response. While numerous drugs have been associated with BP in the literature, causality and pathogenic mechanisms remain elusive in most cases. Dipeptidyl peptidase 4 inhibitors (DPP4i), in particular, are the most frequently reported drugs related to BP and, therefore, have been extensively investigated. They can potentially trigger BP through the impaired proteolytic degradation of BP180, combined with immune dysregulation. DPP4i-associated BP can be categorized into true drug-induced BP and drug-triggered BP, with the latter resembling classic BP. Antineoplastic immunotherapy is increasingly associated with BP, with both B and T cells involved. Other drugs, including biologics, diuretics and cardiovascular and neuropsychiatric agents, present weaker evidence and poorly understood pathogenic mechanisms. Further research is needed due to the growing incidence of BP and the increasing identification of new potential triggers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousDipeptidyl-Peptidase IV InhibitorsAutoimmune DiseasesHumansAutoantigensAutoantibodies

Stichwörter der Autor:innen

autoimmune blistering diseasesbiologicsbullous pemphigoiddipeptidyl peptidase 4 inhibitorsdiureticsdrug-associated bullous pemphigoiddrug-induced bullous pemphigoidgliptinsimmune checkpoint inhibitorsimmunotherapy

Substanzen

AutoantigensDipeptidyl-Peptidase IV InhibitorsAutoantibodies

Autor:innen und Institutionen

  • Dermatology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain.

ORCID-Profile: Asuncion Ballester-Martinez, Emilio Garcia-Mouronte, Emilio Berna-Rico

Zitieren

APA

de Nicolas-Ruanes, B., Ballester-Martinez, A., Garcia-Mouronte, E., Berna-Rico, E., Azcarraga-Llobet, C., & Fernandez-Guarino, M. (2023). From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316786

Vancouver

de Nicolas-Ruanes B, Ballester-Martinez A, Garcia-Mouronte E, Berna-Rico E, Azcarraga-Llobet C, Fernandez-Guarino M. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316786

BibTeX
@article{deNicolasRuanes2023,
  author = {de Nicolas-Ruanes, Belen and Ballester-Martinez, Asuncion and Garcia-Mouronte, Emilio and Berna-Rico, Emilio and Azcarraga-Llobet, Carlos and Fernandez-Guarino, Montserrat},
  title = {From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242316786}
}
Kostenlos starten →